Mirum Pharmaceuticals announced two significant pipeline updates: the U.S. FDA approval of Atebrioz™ (zilurgisertib) for fibrodysplasia ossificans progressiva (FOP), and positive primary endpoint results from the Phase 3 AZURE-1 study of brelovitug for chronic hepatitis delta virus (HDV).
Key Details
- Atebrioz™ FDA Approval: The drug was approved on September 25, 2026, to treat FOP in adults and children 12 years and older. U.S. commercial launch is expected in October 2026, with an estimated annual revenue potential of over $200 million.
- Brelovitug Phase 3 Results: The AZURE-1 study met its primary endpoint, with 56% of patients on the 300 mg dose achieving a combined virologic and ALT normalization response at 24 weeks, compared to 0% in the delayed treatment arm (p<0.0001).
- Brelovitug Next Steps: A Biologics License Application (BLA) is planned for submission to the FDA in the first half of 2027, with a potential U.S. launch in Q4 2027. The company estimates brelovitug's annual revenue potential to be over $1 billion.